BioWorld

Oct. 7, 2003

View Archived Issues

Ingenium Broadens Relationship With Elan For Target Validation

Read More

Pennsylvania Biotech Incubators Rising From Tobacco Settlement

Read More

Other News To Note

Read More

Appointments And Advancements

Read More

BioVex Raises £17M, Aims For Phase II OncoVEX Trial

LONDON - BioVex Ltd. raised £17 million in third-round funding, giving it the means to start a U.S. Phase II trial of its lead cancer vaccine, OncoVEX, and move ImmunoVEX into Phase I work. (BioWorld Today) Read More

Chiron, Patients Fight For Proleukin Reimbursement

Read More